Account: your health data stays in your browserGDPR / Privacy

Questionnaire and diary are encrypted with your password and stored only in this browser. The site owner does not receive them.

Updated October 2026

Retatrutide Research News

Key results of the Eli Lilly Phase 3 programme (TRIUMPH, TRANSCEND-T2D) with links to primary sources.

Regulatory status: Retatrutide is not approved by any regulator. Eli Lilly plans to submit a BLA to the FDA in Q1 2027. The information is for reference only and is not medical advice.

29 September 2026TRIUMPH-2

Full TRIUMPH-2 results presented at EASD and published in The Lancet

Lilly presented detailed Phase 3 data in adults with type 2 diabetes and obesity (1,152 participants, 80 weeks) at the EASD meeting in Milan.

Weight loss: 12.7% (4 mg), 19.1% (9 mg), 20.8% (12 mg); placebo 4.0%.
HbA1c fell by 1.4% (4 mg), 1.6% (9 mg) and 1.5% (12 mg); up to 40.0% reached <5.7%.
In participants with BMI ≥ 35 on 12 mg: −23.4%. 59.5% on 12 mg no longer met the BMI criteria for obesity.
Adverse events at 12 mg: nausea 28.0%, diarrhea 33.6%, vomiting 15.7%, dysesthesia 7.3%; discontinuation due to AEs 7.7% (placebo 4.9%).

Source: Eli Lilly

23 July 2026TRIUMPH-2 / TRIUMPH-3

Two more successful Phase 3 trials; FDA submission planned for Q1 2027

Topline TRIUMPH-2 and TRIUMPH-3 results met the primary endpoint. Lilly said the clinical data package for obesity, knee osteoarthritis pain and sleep apnea is now complete.

TRIUMPH-3 (severe obesity and CVD, 1,949 participants): −21.6% (9 mg) and −22.6% (12 mg) at 80 weeks; placebo −3.2%.
TRIUMPH-2: up to −20.8% (12 mg) with HbA1c reduction up to 1.6%.
Lilly is completing the CMC package and plans to submit a BLA to the FDA in Q1 2027.

Source: Eli Lilly

6 June 2026TRIUMPH-1 · ADA

Additional data: knee pain, sleep apnea and type 2 diabetes

Lilly reported additional Phase 3 results showing improvement in knee osteoarthritis pain, obstructive sleep apnea severity and type 2 diabetes measures.

WOMAC pain score fell by up to 4.3 points (73.1%).
Apnea-hypopnea index fell by up to 36.1 events per hour (60.6%) in moderate-to-severe sleep apnea.
In TRIUMPH-1 on 12 mg, 65.3% of participants reached a BMI below 30.

Source: Drugs.com (пресс-релиз Lilly)

21 May 2026TRIUMPH-1

TRIUMPH-1: up to 28.3% weight loss at 80 weeks

The largest trial of the programme (2,339 adults with obesity or overweight, without diabetes) met its primary and key secondary endpoints.

Weight loss: 19.0% (4 mg), 25.9% (9 mg), 28.3% (12 mg); placebo 2.2% (efficacy estimand).
45.3% on 12 mg lost ≥ 30% of body weight; in the 104-week extension (BMI ≥ 35, 532 participants) — 30.3%.
Nausea on 12 mg 42.4% (placebo 14.8%), dysesthesia 12.5% (placebo 0.9%); discontinuation due to AEs 11.3% (placebo 4.9%).

Source: Eli Lilly

19 March 2026TRANSCEND-T2D-1

First Phase 3 trial in type 2 diabetes: HbA1c down by up to 2.0%

In the 40-week trial of 537 participants retatrutide beat placebo on HbA1c and body weight; no weight-loss plateau was observed.

HbA1c (baseline 7.9%): −1.7% (4 mg), −2.0% (9 mg), −1.9% (12 mg); placebo −0.8%.
Weight: −11.5%, −15.5%, −16.8%; placebo −2.5%.
Discontinuation due to AEs: 2.2% (4 mg), 4.5% (9 mg), 5.1% (12 mg); placebo 0%.

Source: Eli Lilly

11 December 2025TRIUMPH-4

TRIUMPH-4: first successful Phase 3 trial — weight up to −28.7%, knee pain up to −75.8%

In 445 participants with obesity and knee osteoarthritis retatrutide met both co-primary endpoints at 68 weeks.

Weight: −26.4% (9 mg) and −28.7% (12 mg); placebo −2.1%.
WOMAC pain: −75.8% (9 mg) and −74.3% (12 mg); placebo −40.3%.
Completely free of knee pain (post-hoc): 14.1% (9 mg), 12.0% (12 mg) vs 4.2% on placebo.

Source: Eli Lilly